Am J C1in Onca/ (CCT) /8(3 The evaluation of drug efficacy in patients with advanced prostatic cancer who have progressed to hormonal therapy is difficult, although palliation of the pain related to bone involvement stili represents an important endpoint. In this study, epirubicin (EpiADM) plus medroxyprogesterone ac etate (MPA) were given to advanced prostatic cancer patients with symptomatic bone involvement who had progressed to hormonal therapy. EpiADM was administered at a dose of 30 mgjm 2 i.v. weekly and MPA at a daily dose of 1,000 mg p.O. for the first month and 500 mg thereafter. Fifty-four patients entered the trial, ali ofwhom were evaluable. Ame lioration of pain and a ~50% reduction in analgesic intake were observed in 52% of cases, with a mean duration of 4 months. Ofthe 28 responsi ve patients, 26 had already received two lines of hormonal therapy or were resistant to first-line therapy. Of the 23 patients with measurable lesions, 6 ob tained a ~50% tumor shrinkage at these sites. The treatment was well tolerated, and no cardiac toxicity was observed up to a total cumulative EpiADM dose of 660 mgjm 2 • In con clusion, this regime n seems to have a palliative effect in pa tients with advanced prostatic cancer who have progressed to hormonal therapy, and it is feasible in an outpatient setting.
In Europe, the estimated incidence ofprostatic can cer is of 85,000 newly diagnosed cases a year, which represents 13% of ali male cancers (1). Approximately 50% of prostatic cancer patients have bone involvement at the ti me of diagnosis (2) . In these cases, the suppres sion of androgenic activity is considered the most ad equate first-line medicaI treatment. Unfortunately, hormonal therapy is successful in only 60-80% ofcases, and the median duration of response is no more than j 2-18 months (3). Relapsing patients, and those re fractory to hormonal therapy, have a poor quality of Iife as a consequence ofbone pain and Iimited survival (4) , and clinicians generally agree on the need to iden tify an effective and safe second-line medicaI treatment.
Over the past decade, a week1y doxorubicin schedule has been proposed as an effective and feasible second line treatment for advanced prostatic cancer (5) . Sub sequent studies with epirubicin (EpiADM) confirmed preliminary observations, and suggested that these compounds were active in relieving pain and achieved a certain tumor regression and a reduction in tumor markers (6, 7) . The weekly schedule appeared to be less cardiotoxic than 3-weekly administrations, and was well tolerated even in an elderly population such as that represented by prostatic cancer patients (8) .
Other studies have suggested that intermediate-high
doses ofmedroxyprogesterone acetate (500-1,000 mgl day) are effective in palliating bone pain in advanced prostatic cancer, with episodic tumor regressions (9 12) . Furthermore, many reports have indicated that medroxyprogesterone decreases testosterone serum 239 ~i:::' : ; ~:~.1~ii~}d~;;Ii", ' ":.
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levels through the inhibition of luteinizing hormone secretion (10, 13, 14) . On the basis of these results, and laboratory data suggesting a good level of synergy between epirubicin and medroxyprogesterone (15) , it was decided to carry out a multicenter study within the ltalian Trials in Medicai Oncology (ITMO) group. The main aim of the stud y was to define the efficacy ofthis combination in ameliorating bone pain and reducing analgesie in take in prostatic cancer patients with symptomatic bone involvement, who had progressed to at least first-line hormonal therapy.
PATIENTS AND METHODS

Eligible Patients
The eligibility criteria included histologically diag nosed prostatic cancer, the presence of symptomatic bone involvement, an age ~ 78 years, an ECOG per formance status (PS) 1-3, progression to at least a first line hormonal therapy, no previous chemotherapy, the absence of previous or concomitant cardiovascular diseases (such as uncontrolled hypertension, dysrhyth mias, myocardial infarction, or congestive heart fail ure), serum creatinine ~ 1.2 mg% and bilirubin ~ 1.5 mgjdl , white blood celi count ~ 4,000 mm 3 , platelets ~ 100.000 mm 3 , hemoglobin ~ 8 gjdl. Patients con comitantly receiving steroids, biphosphonates, vitamin D, or caJcitonin were excluded from the study, as were patients who needed concomitant radiotherapy or who had ended radiotherapy within the 4 weeks preceding study entry.
Staging Procedures and Treatment Scheme
Pretrea tment examinations included a detailed medicaI history with special attention being paid to the assessment of the severity of bo ne pain and the re cording of the type and doses of the analgesics taken. Pain severity was classified according to the McGill Melzack intensity scale: O= no pain ; I = mild; 2 = dis comforting; 3 = distressing; 4 = horrible; 5 = excru ciating (16) . Hemogram and blood chemistry, prostatic specific antigen (PSA), chest radiograph, abdomen pelvis computed tomography scans or ultrasound, and bone radiograph and scan were also performed. Cardiac function was assessed by means ofblood pressure mea surements, electrocardiogram, and the determination of LVEF through myocardial scano Except for the he mogram and blood pressure measurements (which were repeated weekly), these examinations were per formed every 2 months and at the moment oftreatment withdrawaL Weekly assessments were made of the evolution ofbone pain and changes in analgesie medi caments.
Eligible patients were treated with epirubicin 30 mgj m 2 weekly in a bolus intravenous injection and dail y oral doses of medroxyprogesterone 1,000 mg for the first 30 days and 500 mg thereafter. The treatment was administered in an outpatient setting.
Criteria for Response Evaluation
Response was defined as an improvement (recog nized by both the patient and the physician) of at least one grade in bone pain. and a concomitant reduction in the dose ofall analgesics ofat least 50%. In patients not receiving analgesics, response was evaluated only on the basis of changes in bone pain. Pain relief and the reduction in analgesie intake had to be maintained for at least I month before the patient was considered responsi ve. Time to response was calculated from the beginning of treatment to the detection of response .
Response duration was calculated from the ti me of its onset 10 the time in which one or both ofthe respOnse parameters (bone pain or analgesie intake) worsened. Measurable lesions and bone disease were also assessed and evaluated according to WHO criteri a (17) . A de crease in prostatic specific antigen was defined as a red uction of at least 50% in baseline values, confirmed at [wO successive determinations.
Treatment Continuation
In responding patients (i.e. , an amelioration ofbone pa in and a reduction in analgesie intake), epirubicin plus medroxyprogesterone were continued until pro gression (i.e., the worsening ofpain and j or an increase in analgesie intake), or until the total cumulative dose 01" epirubicin reached 990 mgjm 2 In the case of no variation i n pain andjor analgesie intake, treatment was stopped after an epirubicin cumulative dose of 
Toxicity Monitoring
Side effects were reported according to WHO criteria (17) . In particular, in the presence of myelotoxicity, epirubicin treatment was delayed by 1-2 weeks until recovery (white blood celi count ~ 4,000 mm 3 , platelets ~ 100,000 mm 3 , hemoglobin ~ 8 gjdl). In the case of clinically or instrumentally detected cardiac toxicity, treatment was stopped.
Statistical Analysis
Survival was estimated by means of the Kaplan Meier method and calculated for all eligible patients.
Exact 90% confidence limits based on binomial dis tribution were computed for the probability of re sponse.
2ND LINE THERAPY IN ADVANCED PROSTATIC CA
Between-strata comparisons of response probability were perfonned by means of the Fisher exact test for contingency tables.
RESULTS
Patient Characteristics
Between December 1989 and October 1992, 60 pa tients were registered at the ITMO centrai office in Milan; 6 patients were considered ineligible because of the lack of symptomatic bone involvement. Of the 54 eligible patients, ali were evaluated for response and toxicity. The characteristics of the patients are reported in Table l . Ali of the cases had received at least one first-line honnonal therapy, and 29 were resistant to initial hormonal manipulations. Ten of the 54 cases did not routinely require analgesics; the rest were re ceiving nonsteroidal anti-inflammatory drugs or mor phine derivates.
Response to Treatment Table 2 shows subjective responses to treatment both in patients regularly taking analgesics and in those not routinely trea'ed with analgesie drugs. In the latter, response was evaluated by observing variation in pain, recognized by both the patient and the physician, per sisting for at least l month. Table 3 shows those patients who stopped taking analgesics because ofthe complete disappearance of bone pain. As can be seen, 9 of the 44 patients (20%) receiving analgesics at study entry discontinued their use for a median ti me of 5 months. The patients who experienced an amelioration in bone pain and concomitant1y reduced their analgesie intake by at least 50% are reported in Table 4 . Of the 28 re sponding patients, 20 had already received luteinizing honnone-releasing honnone analogues or orchiectomy plus antiandrogen, and 6 of the remaining 8 were re sistant to a first-line hormonal therapy consisting of orchiectomy or antiandrogens.
In order to assess the direct antitumor activity ofthe epiru bicin-medroxyprogesterone com bination, mea surable lesions, bone disease and prostatic specific an tigen were investigated both before and after treatment (the results are reported in Table 5 ). Sone disease was considered with the sole aim of evaluating tumor pro- gression, because the ubiquitous presence of blastic metastases did not allow any sign suggesting recalcifi cation to be identified. Of the patients with baseline measurable lesions, 26% (90% confidence interval: 15 42%) showed a tumor shrinkage of at least 50%. Ofthe 28 subjective responders, 3 patients experienced a tu mor shrinkage ~ 50% (lung in one case, pelvic nodes in the remaining two). In the group of26 nonrespond ers, the total disappearance of tumor lesions was re ported in two cases (liver in one patient and pelvic nodes in the other), and a tumor shrinkage ~ 50% in one case (pelvic nodes). A decrease in prostatic specific antigen was observed in 3 of the 37 cases with high baseline values, ali 3 experiencing a concomitant sub jective response.
Median survival for the 54 evaluable patients was 12 months (Fig. l) .
Cardiac Toxicity
Ofthe 54 evaluable patients, three (5%) experienced cardiac toxicity, which manifested itself in the form of congestive heart failure. In two cases, the damage was detected instrumentally as a consequence of a decrease in L VEF of, respectively, 15% and 26%; in the third patient, congestive heart failure was diagnosed cIinically and confirmed instrumentalIy as a decrease in L VEF of 25%. AlI three patients were undergoing treatment at the time of the discovery; treatment withdrawalled to the complete recovery of alI of them. In none of these cases was congestive heart failure observed below a total cumulative epirubicin dose of 660 mg/m 2 , and two ofthem had reached a total cumulative dose ~ 900 mg/m 2 . The patient who developed congestive heart fai! ure after 660 mg/m 2 of epiru bicin was 72 years old, had not reported any history of heart disease, and his congestive heart failure was diagnosed instrumentally as a decrease in L VEF of 15%.
No other cardiac toxicity was detected.
Other Side Effects After a mean of 12 epirubicin cycles (range: 5-33), the folIowing WHO grade 1/2 side effects were ob served: leukopenia (17/6 patients), nausea/vomiting (17/3 patients), alopecia (4/5 patients), hydric retention (6/2 patients), anemia (l/4 patients), thrombocytope nia (5/-patients), mucositis (4/-patients), hypergli cemia (1/-patient). No grade 3-4 side effects were ob served, except in three patients who experienced grade 3 leukopenia; however, two of these patients had pre viously been treated with radiotherapy to the pelvis.
In no case did toxicity determine a patient's_refusal to continue treatment.
DISCUSSION
The evaluation of drug efficacy in advanced prostatic cancer is extremely difficult and uncertain. This is mainly due to the fact that most patients have blastic bone involvement, whereas only 20-30% show visceral or soft tissue lesions (2) . Furthermore, in these latter patients, the evolution ofmeasurable sites is not always correlated to subjective improvement (18) . The same is true for prostatic specific antigen determinations. It has been observed that the assessment ofprostatic spe cific antigen values in patients treated with second-line therapy may not reflect real tumor evolution (19) . It therefore appears to be fundamental to identify specific and objective criteria for the assessment of baseline symptoms and their evolution. To this end, the use of a specific questionnaire has been proposed (20) . In an attempt to evaluate pain improvement by objective means, the patients in our study were considered re sponsive only ifthe amelioration in bone pain was as sociated with a reduction of at least 50% in the doses of alI analgesics. This was possible in 44 patients, since IO cases were not routinely taking any analgesic, and were therefore evaluated only considering pain modi fications.
In the 54 evaluable patients treated with the epirub icin plus medroxyprogesterone combination, we ob served a 52% subjective response rate; the mean ti me to response was 4 weeks, and the mean response du ration 4 months. Tumor shrinkage > 50% was obtained in 26% of patients with measurable lesions. The role of epirubicin in the amelioration of performance status and in the induction of objective responses stilI requires definition. Further investigations are needed in order to assess whether a more feasible and less expensive single-agent treatment with medroxyprogesterone could obtain the same results as those observed in this study with the combination. In our opinion, epirubicin played a relevant role in inducing the 26% objective tumor shrinkage observed in this trial; previous expe riences with medroxyprogesterone, although demon- strating palliation of pain, have reported objective tu mor regressions only in sporadic cases (9) (10) (11) (12) .
As far as side effects were concerned, the treatment was welI tolerated and feasible. Three cases of cardio toxicity were reported, but none ofthem occurred be fore the total cumulative dose ofepirubicin had reached 660 mg/m 2 , and two of them only after a total cu mulative dose ~ 900 mg/m 2 • It must be emphasized that only I of 54 patients showed a symptomatic congestive heart failure . In alI cases, the damage was reversible on treatment withdrawal. It is therefore sug gested that patients should be monitored by means of myocardial scan after a total cumulative dose of 480 mg/m 2 is reached, and thereafter at every increase of 120 mg/m 2 up to 840 mg/m 2 , when the treatment could be stopped. On the basis of the presented data, this should practicalIy eliminate cardiac toxicity. Other noncardiologic side effects were mild, leukopenia being the only grade III side effect reported (in 3 of 54 pa tients). Even grade II side effects were unusuaI, being observed in Iess than 12% of cases. Anemia (grade 1 2) and thrombocytopenia (grade I) were observed in 5 patients, respectively, but in these cases it remains difficult to assess whether this was determined by treat ment toxicity or by bone marrow infìltration.
Other authors have already reported on the com bination epirubicin plus medroxyprogesterone in 30 patients who had progressed to hormonal therapy, al though the drugs were given sequentially rather than concomitantly. Their resuIts were equivalent, with 25/ 30 patients showing subjective improvement and ep isodic regressions oftumors and markers. The achieve ment of subjective improvement did not lead to any improvement in survival for this set of patients (21) .
In two randomized studies, a comparison was made between epirubicin plus medroxyprogesterone and es tramustine inthe treatment of patients who had pro gressed to hormonal therapy (22 ,23) . It was observed that the combination appeared to be superior to estra mustine in inducing subjective improvement and pro longing time to progression. Furthermore, one ofthese two randomized studies suggests that the combination of epirubicin and medroxyprogesterone was more ef fective than single epirubicin administration (22) .
In conc1usion, this paper suggests that the com bi nation ofepirubicin and medroxyprogesterone may be active and feasible in the palliation of advanced pros tatic cancer pretreated with hormonotherapy. For the future, it is to be hoped that the duration of su bjective response wilI be improved. and that an assessment can be made as to whether a singIe-agent treatment with 12 16 20 24 28 32
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Am J Clin Dlleol (CCT). Vol. 18. No. l. 1995 medroxyprogesterone at high doses, certainly less ex pensive and better tolerated than the combination, may be similarly effective. The study also outlines the need to determine more adequate response criteria, based on subjective and objective parameters, to be adopted for the evaluation of drug efficacy in the second-line treatment of advanced prostatic cancer.
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